Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Biometrics. 2011 Mar 14;67(4):1638–1646. doi: 10.1111/j.1541-0420.2011.01580.x

Table 3.

Simulation results for the IA tPA trial. Under each scenario, utrue(c, q) denotes the expected utility of treating a patient with the combination (c, q). The value of the utility for the combination with the highest utility is highlighted in bold. Utilities of combinations that are too toxic or have insufficient effiectiveness in the scenario have a gray background

Scenario q c
% none
0.2 0.3 0.4 0.5
1
Prior
means
0.1 utrue(c, q)
% Sel (No. Pats.)
46.9
2% (3.2)
51.5
2% (1.6)
59.2
7% (3.4)
64.4
29% (8.7)
6
0.2 utrue(c, q)
% Sel (No. Pats.)
56.1
2% (0.8)
60.5
2% (0.8)
65.1
11% (4.5)
70.6
38% (11.5)
2
Safe,
high c and
q=.2 best
0.1 utrue(c, q)
% Sel (No. Pats.)
49.0
1% (2.6)
54.9
1% (1.2)
62.4
4% (2.3)
71.5
17% (5.9)
2
0.2 utrue(c, q)
% Sel (No. Pats.)
52.6
1% (0.5)
58.4
1% (0.6)
65.9
13% (5.3)
73.8
60% (16.9)
3
Safe,
middle c and
q=.1 best
0.1 utrue(c, q)
% Sel (No. Pats.)
57.3
3% (2.4)
68.9
8% (3.6)
70.1
33% (9.0)
64.0
33% (9.3)
9
0.2 utrue(c, q)
% Sel (No. Pats.)
57.1
2% (0.5)
68.6
2% (0.9)
69.7
7% (5.4)
63.5
3% (2.8)
4
Safe,
low c and
q=.1 best
0.1 utrue(c, q)
% Sel (No. Pats.)
61.1
43% (14.4)
58.7
7% (3.3)
51.6
6% (3.4)
48.0
5% (2.8)
12
0.2 utrue(c, q)
% Sel (No. Pats.)
58.2
22% (5.0)
53.9
3% (1.5)
49.5
2% (2.2)
45.0
1% (0.9)
5
Unsafe
0.1 utrue(c, q)
% Sel (No. Pats.)
44.8
4% (6.5)
45.2
1% (1.5)
45.2
1% (2.0)
45.0
1% (2.2)
91
0.2 utrue(c, q)
% Sel (No. Pats.)
45.2
1% (0.9)
45.2
0% (0.4)
45.0
0% (0.8)
44.3
0% (0.6)
6
Safe, but
no (c, q)
acceptable
0.1 utrue(c, q)
% Sel (No. Pats.)
38.2
0% (2.8)
40.0
0% (1.1)
41.9
1% (1.6)
43.3
7% (5.2)
83
0.2 utrue(c, q)
% Sel (No. Pats.)
39.3
0% (0.4)
41.2
0% (0.4)
43.1
1% (1.4)
44.4
7% (4.3)